MDM2 and Nephroblastoma: Furthermore, p53, EGFR and MDM2 are also predictive markers in breast cancer (38), lung cancer (39), blastomatoid pulmonary carcinosarcoma (40), Wilms’ tumor (41), anaplastic thyroid carcinoma (42), bladder cancer (43) and prostate cancer (44).